查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1969410

抗生素抗药性市场：依产品类型、病原体类型、感染疾病类型和最终用途划分－2026-2030年全球预测

Antibiotic Resistance Market by Offering, Pathogen Type, Infection Type, End Use - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年抗生素抗药性市场价值为 75.1 亿美元，预计到 2025 年将成长至 79.6 亿美元，年复合成长率为 6.12%，到 2030 年将达到 107.3 亿美元。

主要市场统计数据
基准年 2024 75.1亿美元
预计年份：2025年 79.6亿美元
预测年份 2030 107.3亿美元
复合年增长率 (%) 6.12%

抗生素抗药性问题日益严峻，正在医疗保健系统中蔓延，这是全球相关人员面临的关键问题。

随着抗生素抗药性以前所未有的速度加速发展，全球医疗卫生系统正面临日益严峻的危机。曾经对标准疗法敏感的病原体正在进化出新的机制，以逃避曾经可靠的药物武器。结果，病患住院时间延长、医疗成本飙升、死亡率上升，这些都给各国带来了沉重的负担。在此背景下，理解科学创新、政策改革和临床实践之间的相互作用至关重要。

揭示抗生素开发平臺的变革性转变：法规结构和全球卫生政策正在重塑治疗策略和市场现实。

科学突破、监管调整和不断变化的资金筹措机制的协同作用正在重塑抗生素领域的模式。近年来，适应性试验设计加速了候选药物的筛检，而人工智慧和机器学习平台则简化了标靶辨识和先导化合物优化流程。同时，监管机构正在推出奖励以促进新药研发，并强调转向基于价值的核准途径和快速审查模式转移。

评估美国关税政策在 2025 年对抗生素供应链、研发投资和市场进入。

美国2025年实施的关税措施为抗生素供应链格局带来了新的变数。关键中间体、最终製剂和主要原料关税的提高波及整个生产流程，推高了单位成本，挤压了利润空间。成本基数的扩大促使采购部门重新谈判供应商合同，并探索替代采购方式，从而改变了现有的供应链关係。

透过明确药物类别、病原体类型、传染性变异株和最终用途类别的市场细分，我们旨在确定目标机会和策略挑战。

一个稳健的细分框架突显了战略潜力，并明确指出了抗药性挑战的领域。从药物类别来看，Aminoglycosides对革兰氏阴性菌具有强效杀菌活性，但其治疗指数较窄，需密切监测。头孢菌素类抗菌频谱广，但在医院获得性感染中抗药性不断上升。联合治疗因其对多重抗药性细菌的协同作用而日益重要，而醣肽儘管存在肾毒性的担忧，仍然是治疗方法严重革兰氏阳性病菌感染的主要药物。Oxazolidinone、磺胺类药物和四环霉素在作用机转和安全性方面各有特点，需要根据具体情况制定个人化的治疗方案。

为了突显成长要素和新兴挑战，我们将分析美洲、欧洲、中东和非洲以及亚太地区的区域市场动态。

区域差异持续影响抗生素抗药性的动态变化和策略重点。在美洲，完善的监管途径和报销机制支持先进治疗创新技术的应用。然而，门诊环境中频谱抗生素的广泛使用正在加速抗药性表型的出现，导致更严格的合理用药指南和处方笺限制。同时，拉丁美洲市场面临不稳定的供应链和监管执法不力的问题，加剧了区域高风险病原体的出现。

透过分析领先的製药公司和新兴的抗生素研发和商业化创新者，阐明竞争策略、产品系列和合作网络。

老牌製药公司凭藉着多元化的产品系列和广泛的全球布局，不断巩固其在抗生素市场的地位。这些行业领导者优先考虑在现有药物类别的基础上进行渐进式改进，同时投资于噬菌体疗法和抗菌肽等突破性治疗方法。同时，新兴生技公司则专注于精准标靶作用机制，并利用先进的筛检平台发现不易产生抗药性的新型骨架，从而在市场中占有一席之地。

为产业领导者提供的实用策略建议：促进合理使用抗生素、鼓励创新、加强合作、降低抗药性风险。

产业领导者必须采取多管齐下的策略方法，才能有效应对抗生素抗药性所带来的挑战。首先，加强合理使用抗菌药物是首要任务。这包括将决策支援工具整合到电子健康记录中，以指导处方医生选择最佳剂量方案和窄频谱药物。其次，企业应加速早期药物研发平台的投资，优先开发能够绕过现有抗药性机制的新标靶和创新治疗方法。

严谨的调查方法详情：为了确保分析的稳健性，我们采用了调查方法。

本报告基于严谨的多层次调查方法，旨在确保分析的可靠性和事实的准确性。主要研究工作包括对30多位高阶主管进行深入访谈，其中包括製药公司高阶主管、临床微生物学家、政策顾问以及感染疾病控制领域的关键意见领袖（KOL）。这些访谈提供了关于策略重点、营运挑战和市场预测的定性背景资讯。

我们将整合抗生素抗药性恶化、市场转型和策略路径的关键见解，使决策者能够获得清晰的见解，从而支持积极主动的规划。

抗生素抗药性已超越单纯的临床问题，成为政策、经济和公共卫生交叉领域的严峻挑战。在这种不断变化的情况下，相关人员需要采取综合策略。具体而言，该策略需要结合创新研究、快速监管反应和健全的控制系统，以加速新治疗方法的研发，同时保障现有治疗方法的有效性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 抗生素抗药性市场：依产品/服务分类

  • 联合治疗
  • 药物
    • Aminoglycosides
    • β-内酰胺
    • Fluoroquinolones
    • 醣肽
    • 大环内酯类
    • Oxazolidinone系列
    • 多粘菌素
    • 磺胺类药物药物
    • 四环霉素
  • 免疫调节剂
  • 单株抗体
  • 噬菌体疗法

第九章：按病原体类型分類的抗生素抗药性市场

  • 鲍曼鲍氏不动桿菌
  • 大肠桿菌（E. coli）
  • 肺炎克雷伯菌
  • 铜绿假单胞菌
  • 金黄色葡萄球菌
  • 肺炎链球菌

第十章：依感染疾病类型分類的抗生素抗药性市场

  • 急性细菌性皮肤及皮肤组织感染疾病（ABSSSI）
  • 血液感染疾病（BSI）
  • 艰难梭菌感染疾病（CDI）
  • 社区型细菌性肺炎（CABP）
  • 复杂性尿道感染（cUTI）

第十一章 抗生素抗药性市场：依最终用途划分

  • 门诊部
  • 诊断检查室
  • 医院和诊所
  • 研究机构

第十二章：抗生素抗药性市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：抗生素抗药性市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：抗生素抗药性市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国抗生素抗药性市场

第十六章：中国抗生素抗药性市场

第十七章 竞争格局

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Basilea Pharmaceutica Ltd
  • bioMerieux SA
  • Cipla Limited
  • Cumberland Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Innoviva, Inc.
  • Johnson & Johnson Services, Inc.
  • Novo Holdings A/S
  • Pfizer Inc.
  • Sandoz AG
  • Shionogi & Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-535C629188E6

The Antibiotic Resistance Market was valued at USD 7.51 billion in 2024 and is projected to grow to USD 7.96 billion in 2025, with a CAGR of 6.12%, reaching USD 10.73 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 7.51 billion
Estimated Year [2025] USD 7.96 billion
Forecast Year [2030] USD 10.73 billion
CAGR (%) 6.12%

Unveiling the Escalating Challenge of Antibiotic Resistance Across Healthcare Systems and the Critical Imperatives for Stakeholders Worldwide

Healthcare systems around the globe are confronting a mounting crisis as antibiotic resistance accelerates at an unprecedented pace. Pathogens that were once susceptible to standard treatments are evolving mechanisms to evade the once-reliable weapons in our pharmaceutical arsenal. As a result, communities face longer hospital stays, higher medical costs, and a growing mortality burden. In this context, understanding the interplay of scientific innovation, policy reform, and clinical practice has become critical.

Stakeholders across the continuum-from policy-makers to hospital administrators, from research institutions to pharmaceutical executives-must navigate this volatile environment. They require not only real-time visibility into emerging resistance patterns but also a holistic strategy that aligns discovery pipelines with stewardship initiatives. This introductory section lays the groundwork by framing antibiotic resistance as both a public health emergency and a catalyst for transformative industry responses.

Mapping the Transformative Shifts in Antibiotic Development Pipelines Regulatory Frameworks and Global Health Policies Reshaping Therapeutic Strategies and Market Realities

The antibiotic landscape is being reshaped by a confluence of scientific breakthroughs, regulatory recalibrations, and evolving funding mechanisms. In recent years, adaptive trial designs have accelerated candidate screening, while artificial intelligence and machine learning platforms have streamlined target identification and lead optimization. Simultaneously, regulatory bodies have introduced incentives to stimulate development of novel agents, underscoring a paradigm shift toward value-based approval pathways and expedited reviews.

Moreover, collaborations between public institutions, non-profit consortia, and private enterprises are forging new models for risk sharing and resource pooling. These partnerships are fundamental to overcoming the traditional barriers of cost and complexity, especially in late-stage clinical trials where financial exposure can be prohibitive. Accordingly, we are witnessing a strategic realignment in which stakeholder networks are moving beyond transactional alliances to enduring consortiums, thereby distributing both risk and reward more equitably across the antibiotic innovation ecosystem.

At the same time, global health policies are adjusting to the reality that stewardship and access must be balanced. Initiatives aimed at curbing overuse are now being integrated with mechanisms to ensure equitable distribution, particularly in low- and middle-income nations. The result is a more nuanced regulatory environment that demands adaptive commercial strategies and informed advocacy efforts to synchronize market entry with public health objectives.

Assessing the Far-Reaching Consequences of United States Tariff Policies on Antibiotic Supply Chains R&D Investments and Market Accessibility in 2025

United States tariff measures introduced in 2025 have introduced a new variable into the antibiotic supply chain equation. By raising duties on critical intermediates, finished dosage forms, and key raw materials, these policies have cascaded through manufacturing workflows, elevating unit costs and exerting pressure on profit margins. The increased cost base has spurred procurement teams to renegotiate supplier contracts and explore alternative sourcing arrangements, thereby altering entrenched supply-chain relationships.

In parallel, the tariff landscape has prompted multinational companies to reassess their production footprints. Some organizations have initiated feasibility studies to relocate manufacturing closer to end markets or to establish dual-sourcing agreements to mitigate exposure. Consequently, lead times have lengthened for certain molecule classes, introducing variability in inventory cycles and compelling downstream stakeholders to build additional stock buffers to safeguard against potential disruptions.

Perhaps most impactful is the ripple effect on research and development budgets. As companies absorb tariff-related cost increases, discretionary funding for early-stage research faces tighter scrutiny. Projects targeting high-risk pathogen classes may experience reprioritization, while investment committees demand clearer return-on-investment thresholds. This environment compels a recalibration of portfolio strategies, emphasizing asset triage and the pursuit of collaborative funding mechanisms to share developmental costs and expedite time-to-proof of concept.

Deconstructing Market Segmentation Across Drug Classes Pathogen Types Infection Variants and End Use Categories to Illuminate Targeted Opportunities and Strategic Imperatives

A robust segmentation framework illuminates distinct pockets of strategic potential and resistance challenges. Across drug classes, Aminoglycosides exhibit potent bactericidal action against Gram-negative organisms but carry a narrow therapeutic index that necessitates vigilant monitoring. Cephalosporins offer broad-spectrum coverage yet have encountered elevated resistance rates in hospital-acquired infections. Combination Therapies are increasingly favored for their synergistic efficacy against multidrug-resistant strains, while Glycopeptides remain a mainstay for severe Gram-positive infections despite concerns of nephrotoxicity. Oxazolidinones, Sulfonamides, and Tetracyclines each present unique profiles in terms of mechanism of action and safety considerations, prompting tailored stewardship approaches.

On the pathogen front, Acinetobacter baumannii has emerged as a formidable adversary in critical care settings, leveraging adaptive efflux pumps and biofilm formation to thwart intervention. Escherichia coli continues to drive community and hospital onset urinary tract infections, with plasmid-mediated resistance genes proliferating across geographic regions. Klebsiella pneumoniae maintains a high prevalence in ventilator-associated pneumonia, often harboring carbapenemase enzymes that render last-resort treatments ineffective. Pseudomonas aeruginosa's intrinsic resistance coupled with its ability to acquire novel determinants has cemented its status as a priority pathogen. Meanwhile, Staphylococcus aureus and Streptococcus pneumoniae persist as leading causes of both invasive and non-invasive infections, despite decades of targeted vaccine and antibiotic development.

Infection type segmentation reveals that Acute Bacterial Skin & Skin Structure Infections pose a persistent challenge in outpatient and surgical wound contexts, while Bloodstream Infections demand urgent, broad-spectrum coverage to prevent systemic spread. Clostridioides difficile Infection has surged in frequency and severity, prompting focus on narrow-spectrum therapies and microbiome-based interventions. Community-Acquired Bacterial Pneumonia remains a critical driver of hospital admissions, particularly among vulnerable elderly populations, and Complicated Urinary Tract Infections underscore the need for agents with both potent activity and favorable safety profiles.

End-use categories further refine strategic focus. Ambulatory Care Centers are driving demand for oral formulations and outpatient infusion services. Diagnostic Laboratories play an increasingly central role in rapid pathogen identification and susceptibility profiling, accelerating the shift from empirical to precision prescribing. Hospitals & Clinics continue to dominate acute-care utilization, necessitating robust formulary strategies and integrated stewardship protocols. Research Institutes serve as incubators for next-generation modalities, advancing preclinical platforms that may redefine the future of antibiotic discovery.

Delineating Regional Market Dynamics Across the Americas Europe Middle East Africa and Asia Pacific to Highlight Growth Drivers and Emerging Challenges

Regional heterogeneity continues to shape antibiotic resistance dynamics and strategic priorities. In the Americas, well-established regulatory pathways and reimbursement frameworks support the adoption of advanced therapeutic innovations. However, the pervasive use of broad-spectrum agents in outpatient settings has accelerated the emergence of resistant phenotypes, leading to more stringent stewardship guidelines and formulary restrictions. Meanwhile, Latin American markets are grappling with inconsistent supply chains and variable regulatory enforcement, contributing to localized outbreaks of high-risk pathogens.

Across Europe, Middle East & Africa, fragmented healthcare infrastructures and varying levels of access to diagnostic technology complicate coordinated stewardship efforts. In Western Europe, centralized procurement and pan-regional surveillance networks have enabled more cohesive responses to resistance trends. By contrast, emerging markets in the Middle East and Africa face challenges in laboratory capacity, cold-chain logistics, and regulatory alignment, driving reliance on off-patent generics and impeding uptake of novel agents.

Asia-Pacific presents a dual narrative of rapid innovation and persistent public health hurdles. Markets such as Japan, Australia, and South Korea boast sophisticated R&D ecosystems and proactive policy frameworks. At the same time, densely populated regions in Southeast Asia and South Asia experience high rates of antibiotic consumption, often driven by over-the-counter availability and under-resourced stewardship programs. This juxtaposition underscores both the promise of regional leadership in next-generation therapies and the imperative for coordinated cross-border initiatives to curb resistance transmission.

Analyzing Leading Pharmaceutical Players and Emerging Innovators Across Antibiotic R&D and Commercialization to Uncover Competitive Strategies Product Portfolios and Collaborative Networks

A cadre of established pharmaceutical companies continues to anchor the antibiotic market through diversified product portfolios and expansive global reach. These industry leaders prioritize a balanced approach between incremental improvements to existing classes and investments in breakthrough modalities, such as bacteriophage therapies and antimicrobial peptides. Meanwhile, emerging biotechs are carving out niche positions by focusing on precision-targeted mechanisms, leveraging advanced screening platforms to unearth novel scaffolds with reduced propensity for resistance development.

Strategic alliances have become a hallmark of the competitive landscape. Cross-sector partnerships between pharma giants and biotech innovators facilitate agile progression of assets through preclinical validation into early clinical trials. At the same time, consortium models-often supported by government grants and non-profit funding-are aggregating pooled resources to de-risk the development of ultra-narrow-spectrum candidates against priority pathogens.

In the commercialization phase, companies are adopting dynamic pricing and value-based contracting arrangements, linking reimbursement to real-world outcomes data. Such initiatives reflect a growing emphasis on aligning stakeholder incentives to reward both clinical efficacy and responsible utilization. As a result, entities that can demonstrate robust pharmacovigilance mechanisms and post-market surveillance capabilities are gaining a competitive edge, reinforcing the notion that superior product performance extends beyond the laboratory bench.

Formulating Actionable Strategic Recommendations for Industry Leaders to Enhance Antibiotic Stewardship Drive Innovation Strengthen Collaborations and Mitigate Resistance Risks

Industry leaders must adopt a multifaceted strategic playbook to navigate the antibiotic resistance landscape effectively. First, strengthening antimicrobial stewardship programs is paramount; this includes embedding decision-support tools within electronic health records to guide prescribers toward optimal dosing regimens and narrow-spectrum selections. Second, firms should accelerate investment in early-stage discovery platforms, prioritizing novel targets and innovative modalities that circumvent existing resistance mechanisms.

Simultaneously, fostering cross-sector collaboration will amplify impact. Pharmaceutical companies, academic institutions, and non-profit foundations should co-create funding consortia aimed at de-risking high-value projects. By sharing precompetitive data and co-developing clinical trial networks, these alliances can streamline development timelines and distribute financial exposure.

Engagement with regulatory bodies is equally critical. Companies must proactively shape policy dialogues on breakthrough therapy designations, adaptive licensing frameworks, and reimbursement models tied to long-term efficacy data. Clear, evidence-driven advocacy can help align public health objectives with commercial incentives, ensuring that novel agents reach patients without undue delay.

Finally, leveraging real-world evidence and digital health solutions will differentiate market leaders. Telemedicine platforms, rapid diagnostic integration, and post-market surveillance apps can provide granular usage and outcome data. By harnessing these insights, organizations can refine clinical guidelines, demonstrate value to payers, and reinforce responsible prescribing practices across care settings.

Detailing the Rigorous Research Methodology Combining Qualitative Expert Consultations Quantitative Data Analysis and Comprehensive Secondary Research to Ensure Analytical Robustness

This report is underpinned by a rigorous, multi-layered research methodology designed to ensure analytical robustness and factual precision. Primary research comprised in-depth interviews with over 30 senior executives across pharmaceutical companies, clinical microbiologists, policy advisors, and key opinion leaders in infectious disease management. These conversations provided qualitative context around strategic priorities, operational challenges, and market expectations.

Quantitative data collection drew on a wide array of reputable sources, including peer-reviewed journals, regulatory agency publications, hospital procurement records, and patient outcome registries. Data points were meticulously validated through cross-referencing and triangulation to safeguard against bias or inconsistency. In addition, supply chain analytics were integrated to model cost impacts, inventory flows, and lead-time variability under different tariff scenarios.

Secondary research efforts encompassed a comprehensive review of treatment guidelines, policy whitepapers, and global surveillance reports. Special attention was given to emerging regulatory directives and stewardship frameworks, enabling a nuanced understanding of how shifting policies influence both clinical practice and commercial strategy.

Finally, all insights underwent rigorous peer review by an internal panel of domain experts to confirm accuracy, relevance, and forward-looking applicability. This layered approach ensures that conclusions and recommendations are grounded in both empirical evidence and strategic foresight.

Synthesizing Critical Findings on Antibiotic Resistance Escalation Market Transformations and Strategic Pathways to Equip Decision Makers with Clear Insight for Proactive Planning

Antibiotic resistance has transcended a purely clinical concern to become a defining challenge that intersects policy, economics, and public health. The evolving landscape demands that stakeholders adopt integrated strategies, combining innovative research, agile regulatory engagement, and robust stewardship to safeguard the efficacy of existing therapies while accelerating the advent of new ones.

Strategic segmentation by drug class, pathogen type, infection variant, and end use has revealed differentiated areas of focus, guiding targeted investment and commercialization plans. Meanwhile, regional dynamics underscore the need for tailored approaches that reflect local infrastructure, regulatory environments, and cultural prescribing habits. In this complex ecosystem, leading companies are leveraging partnerships, adaptive trial designs, and digital tools to maintain competitive momentum. Looking ahead, the most successful entities will be those that align stakeholder incentives, embrace data-driven decision making, and foster collaborative networks across the public and private sectors.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibiotic Resistance Market, by Offering

  • 8.1. Combination Therapies
  • 8.2. Drugs
    • 8.2.1. Aminoglycosides
    • 8.2.2. Beta-Lactams
    • 8.2.3. Fluoroquinolones
    • 8.2.4. Glycopeptides
    • 8.2.5. Macrolides
    • 8.2.6. Oxazolidinones
    • 8.2.7. Polymyxins
    • 8.2.8. Sulfonamides
    • 8.2.9. Tetracyclines
  • 8.3. Immunomodulators
  • 8.4. Monoclonal Antibodies
  • 8.5. Phage Therapy

9. Antibiotic Resistance Market, by Pathogen Type

  • 9.1. Acinetobacter Paumannii (A. baumannii)
  • 9.2. Escherichia Coli (E. coli)
  • 9.3. Klebsiella Pneumoniae (K. pneumoniae)
  • 9.4. Pseudomonas Aeruginosa (P. aeruginosa)
  • 9.5. Staphylococcus Aureus (S. aureus)
  • 9.6. Streptococcus Pneumonia (S. pneumoniae)

10. Antibiotic Resistance Market, by Infection Type

  • 10.1. Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
  • 10.2. Bloodstream Infections (BSI)
  • 10.3. Clostridioides difficile Infection (CDI)
  • 10.4. Community-Acquired Bacterial Pneumonia (CABP)
  • 10.5. Complicated Urinary Tract Infections (cUTI)

11. Antibiotic Resistance Market, by End Use

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics
  • 11.4. Research Institutes

12. Antibiotic Resistance Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antibiotic Resistance Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antibiotic Resistance Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Antibiotic Resistance Market

16. China Antibiotic Resistance Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2024
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2024
  • 17.3. Product Portfolio Analysis, 2024
  • 17.4. Benchmarking Analysis, 2024
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Basilea Pharmaceutica Ltd
  • 17.8. bioMerieux S.A.
  • 17.9. Cipla Limited
  • 17.10. Cumberland Pharmaceuticals
  • 17.11. F. Hoffmann-La Roche Ltd
  • 17.12. GlaxoSmithKline plc
  • 17.13. Innoviva, Inc.
  • 17.14. Johnson & Johnson Services, Inc.
  • 17.15. Novo Holdings A/S
  • 17.16. Pfizer Inc.
  • 17.17. Sandoz AG
  • 17.18. Shionogi & Co., Ltd.
  • 17.19. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBIOTIC RESISTANCE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 12. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BETA-LACTAMS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GLYCOPEPTIDES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY OXAZOLIDINONES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY POLYMYXINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PHAGE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACINETOBACTER PAUMANNII (A. BAUMANNII), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ESCHERICHIA COLI (E. COLI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY KLEBSIELLA PNEUMONIAE (K. PNEUMONIAE), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY PSEUDOMONAS AERUGINOSA (P. AERUGINOSA), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STAPHYLOCOCCUS AUREUS (S. AUREUS), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIA (S. PNEUMONIAE), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY ACUTE BACTERIAL SKIN & SKIN STRUCTURE INFECTIONS (ABSSSI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY BLOODSTREAM INFECTIONS (BSI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY CLOSTRIDIOIDES DIFFICILE INFECTION (CDI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 95. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 96. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 97. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AMERICAS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 119. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 120. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 125. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 126. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 127. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 131. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. AFRICA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 143. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 145. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 146. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 147. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. ASEAN ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 150. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 151. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 152. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GCC ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 162. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 163. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 164. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 165. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. BRICS ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 168. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 169. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 170. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. G7 ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 174. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 175. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 176. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NATO ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 180. GLOBAL ANTIBIOTIC RESISTANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED STATES ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 187. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 188. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 189. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 190. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY PATHOGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. CHINA ANTIBIOTIC RESISTANCE MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)